Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.01M Sell
54,520
-7,869
-13% -$921K 3.1% 10
2026
Q1
$7.5M Buy
62,389
+1,144
+2% +$132K 3.24% 12
2025
Q4
$5.93M Sell
61,245
-1,761
-3% -$165K 2.92% 13
2025
Q3
$4.83M Sell
63,006
-1,219
-2% -$100K 2.4% 20
2025
Q2
$4.67M Buy
64,225
+3,328
+5% +$265K 2.43% 18
2025
Q1
$5.2M Buy
60,897
+10,094
+20% +$942K 2.63% 18
2024
Q4
$4.89M Sell
50,803
-20
-0% -$2.06K 2.53% 19
2024
Q3
$5.53M Buy
50,823
+4,541
+10% +$539K 2.85% 14
2024
Q2
$5.99M Sell
46,282
-2,142
-4% -$276K 3.11% 11
2024
Q1
$6.39M Buy
48,424
+348
+0.7% +$42.9K 3.4% 9
2023
Q4
$5.24M Sell
48,076
-668
-1% -$69.3K 3.01% 13
2023
Q3
$5.02M Sell
48,744
-220
-0.4% -$23.7K 3.14% 11
2023
Q2
$5.65M Buy
48,964
+785
+2% +$89.1K 3.4% 10
2023
Q1
$5.22M Sell
48,179
-1,076
-2% -$116K 3.33% 10
2022
Q4
$5.46M Sell
49,255
-75
-0.2% -$7.67K 3.54% 10
2022
Q3
$4.25M Sell
49,330
-60
-0.1% -$5.36K 3.01% 16
2022
Q2
$4.5M Sell
49,390
-540
-1% -$47.9K 3.03% 12
2022
Q1
$4.1M Sell
49,930
-160
-0.3% -$12.6K 2.41% 22
2021
Q4
$3.84M Buy
50,090
+5
+0% +$398 2.12% 23
2021
Q3
$3.76M Sell
50,085
-29
-0.1% -$2.21K 2.3% 21
2021
Q2
$3.9M Sell
50,114
-2,888
-5% -$215K 2.42% 21
2021
Q1
$3.9M Sell
53,002
-6
-0% -$443 2.57% 19
2020
Q4
$4.14M Sell
53,008
-650
-1% -$49.7K 2.95% 13
2020
Q3
$4.25M Sell
53,658
-676
-1% -$53K 3.33% 8
2020
Q2
$4.01M Buy
54,334
+3,786
+7% +$285K 3.2% 9
2020
Q1
$3.71M Sell
50,548
-1,488
-3% -$117K 3.59% 7
2019
Q4
$4.52M Sell
52,036
-531
-1% -$43.6K 3.3% 10
2019
Q3
$4.22M Sell
52,567
-209
-0.4% -$16.8K 3.27% 8
2019
Q2
$4.22M Sell
52,776
-362
-0.7% -$27.7K 3.35% 6
2019
Q1
$4.22M Sell
53,138
-393
-0.7% -$29.4K 3.38% 7
2018
Q4
$3.9M Sell
53,531
-87
-0.2% -$6.14K 3.36% 6
2018
Q3
$3.63M Sell
53,618
-629
-1% -$40.1K 2.9% 14
2018
Q2
$3.14M Sell
54,247
-4,934
-8% -$278K 2.74% 18
2018
Q1
$3.08M Buy
+59,181
New +$3.2M 2.48% 25

Other funds holding MRK

Baugh & Associates's MRK Position: Q2 2026 in Review

Baugh & Associates reduced its Merck (MRK) stake by 13% in Q2 2026, selling an estimated $921K and leaving 54,520 shares worth $7.01M. The position accounts for 3.1% of the portfolio, ranked #10.

Baugh & Associates first reported a position in MRK in Q1 2018 and has held it in 34 quarters since. The position peaked at $7.5M in Q1 2026. 1,617 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Baugh & Associates held 54,520 shares of Merck worth $7.01M as of Q2 2026.
  • Baugh & Associates sold 7,869 Merck shares in Q2 2026, an estimated $921K.
  • Merck made up 3.1% of Baugh & Associates's portfolio in Q2 2026, its #10 holding.
  • Baugh & Associates first reported a position in Merck in Q1 2018 and has held it in 34 quarters since.
  • Baugh & Associates's Merck position peaked at $7.5M in Q1 2026.
  • 1,617 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Baugh & Associates's 13F filing for Q2 2026, filed 13 Jul 2026.